By Roger M. Kaldawy, M.D.

In the late 1990s and early 2000s, LASIK became the crown jewel of refractive surgery. Patients rushed to correct their vision, thrilled by the idea of being free from glasses and contacts. Over time, however, some of LASIK’s limitations became clearer: cutting and thinning of the cornea, potential for worsened dry-eye symptoms, night-vision issues, and concerns about corneal stability — especially in thinner corneas — as well as challenges in achieving precise intraocular lens calculations if cataract surgery is needed later in life.

A new technology has since emerged in the United States — the EVO Visian ICL (often simply called “EVO ICL”) — and its adoption has grown rapidly since FDA approval in 2022. Designed for adults with moderate to high myopia, with or without astigmatism, EVO ICL offers a compelling alternative to LASIK.

What makes EVO ICL different — and increasingly preferable?

Unlike LASIK, EVO ICL does not remove or thin the cornea. The lens is placed behind the iris and in front of the natural crystalline lens, leaving the corneal architecture untouched. There is no flap creation, no tissue removal, and no weakening of the cornea.

Because the cornea remains intact, the risk of corneal ectasia — a rare but serious complication associated with LASIK — is virtually eliminated in properly screened patients. EVO ICL also tends to minimize dry-eye symptoms, since the corneal nerves are not disrupted as they are during laser-based procedures.

Night-vision problems such as glare or halos, often reported after LASIK, are less common with EVO ICL. Because the eye’s optical system remains more natural and unaltered, patients frequently report crisp, high-quality vision even in dim light.

Another major advantage is that EVO ICL is reversible and additive rather than subtractive. The lens can be removed or replaced if needed, preserving the eye’s natural anatomy. This feature becomes especially important later in life when cataract surgery may be needed. Since the cornea is untouched, calculations for premium intraocular lenses — such as multifocal implants that restore both distance and near vision — remain highly accurate.

Across the country, surgeons are reporting rapid growth in EVO ICL procedures since its approval. More patients are asking for it, more practices are offering it, and the procedure has quickly become a mainstream choice for vision correction.

Clinically, LASIK remains an excellent option for patients with mild to moderate myopia, healthy corneal thickness, and no significant dry-eye history. But for patients with thinner corneas, higher prescriptions, greater astigmatism, or those thinking ahead to future cataract surgery, EVO ICL is quickly becoming the preferred option. Many surgeons are now offering it even for mild myopia because of its safety, comfort, and strong outcomes.

In short, LASIK may now represent the past for many patients and practices, while EVO ICL stands as the future of refractive correction. Both have their place, but the shift is unmistakable: more people are choosing EVO ICL for its safety, reversibility, comfort, and compatibility with future vision care.

At Milford Franklin Eye Center, we are proud to be at the forefront of this evolution. Dr. Roger Kaldawy is among the first surgeons in the region to offer EVO ICL technology in our state-of-the-art surgery center. With over 30,000 intraocular procedures — and an even higher number of laser cases — Dr. Kaldawy brings unparalleled experience to this advanced form of refractive surgery. He and his colleagues are committed to helping you achieve your vision goals: reducing your dependence on glasses and contacts while protecting your long-term eye health.

If you’re ready to explore true refractive freedom — and considering a meaningful gift of sight this holiday season — contact us for a consultation and discover why EVO ICL may be the procedure of tomorrow, available today.

For more details, see our ad on this page.

Sponsored articles are submitted by our advertisers. The advertiser is solely responsible for the content of this article.